Science magazine: Blood vessel attack could trigger coronavirus’ fatal ‘second phase’
UC cardiologist weighs in on the cardiovascular impact of COVID-19
Richard Becker, MD, director the University of Cincinnati Heart, Lung and Vascular Institute and UC Health cardiologist, spoke with Science magazine writer Catherine Matacic for a story that looks at the impact COVID-19 has on blood vessels in the body. The novel coronavirus may attack endothelial cells that line the blood vessels and possibly spark inflammation and acute respiratory distress syndrome which kills most patients. The reporter also cited Becker’s recent review of cardiovascular research in the Journal of Thrombosis and Thrombolysis.
Read the entire interview online.
Learn more about the cardiovascular research Becker is co-sponsoring at UC.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.